×
About 9,146 results

ALLMedicine™ Leukemias Center

Research & Reviews  4,379 results

Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and ...
https://doi.org/10.1158/1078-0432.CCR-20-1696
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research; Boal LH, Glod J et. al.

Sep 18th, 2020 - Simultaneously targeting the tumor and tumor microenvironment (TME) may hold promise in treating children with refractory solid tumors. Pexidartinib, an oral inhibitor of tyrosine kinases including Colony Stimulating Factor 1 Receptor (CSF-1R), KI...

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate...
https://doi.org/10.1038/s41375-020-01031-1
Leukemia Largeaud L, Cornillet-Lefebvre P et. al.

Sep 18th, 2020 - We previously reported the benefit of lomustine addition to conventional chemotherapy in older acute myeloid leukemias with nonadverse chromosomal aberrations in the LAM-SA 2007 randomized clinical trial (NCT00590837). A molecular analysis of 52 g...

Notch 1 in cancer therapy: possible clinical implications and challenges.
https://doi.org/10.1124/molpharm.120.000006
Molecular Pharmacology; Gharaibeh LF, Elmadany N et. al.

Sep 11th, 2020 - The Notch family consists of four highly conserved transmembrane receptors, the release of the active intracellular domain requires the enzymatic activity of gamma secretase. Notch is involved in embryonic development and in many physiological pro...

An intact gut microbiome protects genetically predisposed mice against leukemia.
https://doi.org/10.1182/blood.2019004381
Blood Vicente Dueñas C, Janssen S et. al.

Sep 10th, 2020 - The majority of childhood leukemias are precursor B cell-acute lymphoblastic leukemias (pB-ALL) caused by a combination of prenatal genetic predispositions and oncogenic events occurring after birth. Although genetic predispositions are frequent i...

Dynamic prediction of relapse in patients with acute leukemias after allogeneic transpl...
https://doi.org/10.1111/ijlh.13328
International Journal of Laboratory Hematology REFERENCES; Huang A, Chen Q et. al.

Sep 3rd, 2020 - Relapse remains the leading cause of treatment failure after allogeneic hematopoietic stem cell transplantation (alloHSCT) in leukemia. Numerous investigations have demonstrated that minimal residual disease (MRD) before or after alloHSCT is progn...

see more →

Guidelines  19 results

Acute Myeloid Leukemia - AML | ARUPConsult Lab Test Selection
https://arupconsult.com/content/acute-myeloid-leukemia

Jun 30th, 2019 - Acute myeloid leukemias (AMLs) are a heterogeneous group of disorders characterized by the clonal expansion of myeloid blasts (eg, undifferentiated myeloid precursors) in the peripheral blood, bone marrow, and/or other tissues, which results in im...

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
https://jnccn.org/view/journals/jnccn/17/6/article-p721.xml
Journal of the National Comprehensive Cancer Network;

Jun 14th, 2019 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for ...

23rd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
https://www.gotoper.com/conferences/hem/meetings/23rd-international-congress-on-hematologic-malignancies-focus-on-leukemias-lymphomas-and-myeloma

Feb 27th, 2019 - Now in its 23rd year, the annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma provides practitioners who manage hematologic malignancies the practical tools to translate emerging data into the bes...

Hematology Quality Metrics
http://www.hematology.org/Clinicians/Guidelines-Quality/503.aspx
Allen, S.

Feb 20th, 2018 - These clinical performance measures are designed for individual quality improvement. Some of the measures may also be appropriate for accountability if appropriate sample sizes and implementation rules are achieved.

see more →

Drugs  35 results see all →

Clinicaltrials.gov  4,519 results

Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and ...
https://doi.org/10.1158/1078-0432.CCR-20-1696
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research; Boal LH, Glod J et. al.

Sep 18th, 2020 - Simultaneously targeting the tumor and tumor microenvironment (TME) may hold promise in treating children with refractory solid tumors. Pexidartinib, an oral inhibitor of tyrosine kinases including Colony Stimulating Factor 1 Receptor (CSF-1R), KI...

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate...
https://doi.org/10.1038/s41375-020-01031-1
Leukemia Largeaud L, Cornillet-Lefebvre P et. al.

Sep 18th, 2020 - We previously reported the benefit of lomustine addition to conventional chemotherapy in older acute myeloid leukemias with nonadverse chromosomal aberrations in the LAM-SA 2007 randomized clinical trial (NCT00590837). A molecular analysis of 52 g...

Notch 1 in cancer therapy: possible clinical implications and challenges.
https://doi.org/10.1124/molpharm.120.000006
Molecular Pharmacology; Gharaibeh LF, Elmadany N et. al.

Sep 11th, 2020 - The Notch family consists of four highly conserved transmembrane receptors, the release of the active intracellular domain requires the enzymatic activity of gamma secretase. Notch is involved in embryonic development and in many physiological pro...

An intact gut microbiome protects genetically predisposed mice against leukemia.
https://doi.org/10.1182/blood.2019004381
Blood Vicente Dueñas C, Janssen S et. al.

Sep 10th, 2020 - The majority of childhood leukemias are precursor B cell-acute lymphoblastic leukemias (pB-ALL) caused by a combination of prenatal genetic predispositions and oncogenic events occurring after birth. Although genetic predispositions are frequent i...

Dynamic prediction of relapse in patients with acute leukemias after allogeneic transpl...
https://doi.org/10.1111/ijlh.13328
International Journal of Laboratory Hematology REFERENCES; Huang A, Chen Q et. al.

Sep 3rd, 2020 - Relapse remains the leading cause of treatment failure after allogeneic hematopoietic stem cell transplantation (alloHSCT) in leukemia. Numerous investigations have demonstrated that minimal residual disease (MRD) before or after alloHSCT is progn...

see more →

News  193 results

Federal Health Care Cancer Data Trends 2019
https://www.mdedge.com/fedprac/article/209596/federal-health-care-cancer-data-trends-2019?channel=167

Oct 7th, 2019 - Click here to access Federal Health Care Cancer Data Trends 2019 Table of Contents Introduction Cancer in the VA: The Big Picture Hepatocellular Carcinoma Prostate Cancer Multiple Myeloma Lung Cancer in the VA at a National Level Lung Cancer – Reg.

Leukemia Federal Health Care Data Trends
https://www.mdedge.com/fedprac/avaho/article/208837/oncology/leukemia-federal-health-care-data-trends?channel=263
Joao L. Ascensao, MD, PhD, FACP

Sep 25th, 2019 - (function(n){var r="_ion_ionizer",t=n. getElementsByTagName("script"),i;t=t[t.

Cancer centers announce new faculty
https://www.mdedge.com/hematology-oncology/article/206202/business-medicine/cancer-centers-announce-new-faculty?channel=59288
Jennifer Smith

Aug 12th, 2019 - Jorge E. Cortes, MD, is set to become director of the Georgia Cancer Center in Augusta on Sept.

Acute Myeloid Leukemia - AML | ARUPConsult Lab Test Selection
https://arupconsult.com/content/acute-myeloid-leukemia

Jun 30th, 2019 - Acute myeloid leukemias (AMLs) are a heterogeneous group of disorders characterized by the clonal expansion of myeloid blasts (eg, undifferentiated myeloid precursors) in the peripheral blood, bone marrow, and/or other tissues, which results in im...

see more →

Patient Education  1 results see all →